Navigation Links
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
Date:12/13/2011

cent) of evaluable patients had nearly complete inhibition (>90 percent) of tFLT3 levels by the end of the first week of dosing.  Total FLT3 levels, as well as quizartinib-driven decreases in these levels correlated significantly with patients' peripheral blast counts and reductions in peripheral blast counts, respectively.  These findings suggest that the Ambit-developed assay can effectively track effects of drug administration on peripheral disease burden, and that further exploration is merited to determine the potential clinical utility in the future disease management of AML. 

Quizartinib (AC220), a Potent and Specific FLT3 Inhibitor, Enhances the Activity of Combined Cytarabine and Daunorubicin Chemotherapy in a FLT3-ITD Model of AML

Induction chemotherapy with a combination of cytarabine and an anthracycline (e.g. daunorubicin) is the first-line standard of care in the clinical management of AML patients.  To investigate the potential role of quizartinib in this setting, a series of three in vivo preclinical studies were performed using a solid tumor bearing mouse model with a leukemic cell line harboring the FLT3-ITD mutation (MV4-11).  The effect of quizartinib and standard chemotherapy alone and in combination with one another were assessed and compared.  Study 1 explored the effects of a low dose of quizartinib alone (1 mg/kg), cycles of cytarabine (Ara-C) alone (60 mg/kg), and in combination.  Study 2 explored the effects of a low dose of quizartinib alone (0.5 mg/kg), cycles of Ara-C + daunorubicin (DNR) (80 mg/kg and1 mg/kg, respectively) as a regimen alone, and in combination.  Study 3 explored the effects of a high dose of quizartinib alone (10 mg/kg), cycles of Ara-C + DNR (80 mg/kg and 1 mg/kg, respectively) as a regimen alone, and in combination.  In all studies, multiple quizartinib dosing schedules were evaluated, including both the episodic dosing of qu
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
4. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
5. Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back
6. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
7. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
8. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
9. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up ... many of them wrote: "Take better care of my furry companion." ... designer clothes and top-brand carrying cases to take the little canine ... might also feel compelled to buy some pricey toys at the ...
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... the sector for Anti-aging, products and services, presently ... Biggest Marketing ... National Stem,Cell Holding, Inc. (OTC Bulletin Board: NHGI - ... to exclusively license one of,its recently discovered biomaterials which holds ...
... China Genzyme,Corp. (Nasdaq: GENZ ) and ... collaborate to manufacture, develop, and commercialize the,experimental gene ... advanced gene therapy candidate and is currently in ... Europe. Sunway is a privately-held, Shanghai-based biotechnology ...
... Genasense in Relapsed/Refractory Patients, BERKELEY HEIGHTS, N.J., ... announced that the Company has completed the,filing of ... Acting,Director of the Center for Drug Evaluation Research ... The appeal asks that CDER approve the,use of ...
Cached Biology Technology:National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications 2Genzyme and Sunway to Collaborate on Gene Therapy Program in China 2Genzyme and Sunway to Collaborate on Gene Therapy Program in China 3Genzyme and Sunway to Collaborate on Gene Therapy Program in China 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5
(Date:4/18/2014)... emergency contraceptive pills in Peru found that 28 ... substandard quality or falsified. Many pills released the ... active ingredient. One batch had no active ingredient ... drugs, researchers at the Georgia Institute of Technology ... quickly assess suspected counterfeit drugs and then characterize ...
(Date:4/18/2014)... past 20 years, researchers have published soil organic carbon ... suggested that soil organic carbon can be sequestered by ... no-till systems. However, there is a growing body of ... soybean rotations without cover crops, small grains, and forages ... the published rates. , "Some studies have shown that ...
(Date:4/18/2014)... impacts can cause widespread ecological havoc, killing off plants ... new research from Brown University shows that impacts can ... time of an impact. , A research team led ... leaves and preserved organic compounds lodged inside glass created ... could provide a snapshot of environmental conditions at the ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3
... Sebelius today announced one billion dollars of American Recovery ... repair and renovate scientific research laboratories and related facilities ... National Center for Research Resources (NCRR) administered the grants, ... and to help foster scientific advances that may lead ...
... NEW YORK CITY (May 14, 2010)--The New York ... $27 million from the Robertson Foundation, established by Julian ... addition to other support, will provide funding for NYSCF-Robertson ... and the creation of the NYSCF-Robertson Stem Cell Prize. ...
... venomous snakes are legendary for their lethal bites, but not ... Massachusetts Lowell, explains that some cobras defend themselves by spraying ... chance to work with spitting cobras in South Africa, Young ... at his eyes. Protected by a sheet of Perspex, Young ...
Cached Biology News:HHS Secretary Sebelius announces $1 billion in NIH Recovery Act awards for research construction 2HHS Secretary Sebelius announces $1 billion in NIH Recovery Act awards for research construction 3Spitting cobras track first, predict later 2
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
... produces output at 470 nm; includes interface cable ... or installed into rack or desktop boxes ... is an LED that produces either pulsed or ... region -- for fluorescence measurements. The source is ...
... LNA microarray slides for microRNA expression ... incorporate Exiqons unique Locked Nucleic Acid (LNA) ... mismatch discrimination for short microRNA (miRNA) targets. ... 1 g total RNA (no need for ...
... Clear amber to slightly cloudy liquid. ... vials per set, each containing 10 ... in the following proportions by weight: ... (mannide monooleate emulsifier), and 0.1% ...
Biology Products: